Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$21.31
At close: Jun 16, 4:58 PM EDT
$21.27
-0.04-0.21%
Pre-Market: Jun 16, 4:58 PM EDT
Comments
Loading...
Cidara Therapeutics Analyst Ratings and Price Targets | NASDAQ:CDTX | Benzinga
Cidara Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Cidara Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
JMP Securities
RBC Capital
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Cidara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/18/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis47% | → $41 | Assumes | → Buy | Get Alert |
| 06/10/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt32% | — | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2025 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $36 | Maintains | Buy | Get Alert |
| 06/02/2025 | Buy Now | — | JMP Securities | Roy Buchanan42% | $47 → $47 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/27/2025 | Buy Now | — | JMP Securities | Roy Buchanan42% | $47 → $47 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/23/2025 | Buy Now | — | RBC Capital | Gregory Renza50% | $31 → $35 | Maintains | Outperform | Get Alert |
| 05/23/2025 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2025 | Buy Now | — | Guggenheim | Seamus Fernandez61% | $35 → $50 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | Guggenheim | Seamus Fernandez61% | $33 → $35 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | JMP Securities | Roy Buchanan42% | $46 → $47 | Maintains | Market Outperform | Get Alert |
| 04/29/2025 | Buy Now | — | JMP Securities | Roy Buchanan42% | $46 → $46 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/10/2025 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | Citizens Capital Markets | Roy Buchanan42% | → $46 | Initiates | → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $24 → $35 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Needham | Joseph Stringer61% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt32% | — | Assumes | → Overweight | Get Alert |
| 12/13/2024 | Buy Now | — | RBC Capital | Gregory Renza50% | → $34 | Initiates | → Outperform | Get Alert |
| 12/05/2024 | Buy Now | — | WBB Securities | Stephen Brozak77% | $40 → $45 | Maintains | Strong Buy | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | — | Guggenheim | Seamus Fernandez61% | → $33 | Initiates | → Buy | Get Alert |
| 10/22/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $24 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | — | Reiterates | → Overweight | Get Alert |
| 08/14/2024 | Buy Now | — | Needham | Joseph Stringer61% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | — | Reiterates | → Overweight | Get Alert |
| 05/16/2024 | Buy Now | — | Needham | Joseph Stringer61% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | — | WBB Securities | Stephen Brozak77% | → $40 | Maintains | Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | — | Needham | Joseph Stringer61% | $3 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | — | Reiterates | → Overweight | Get Alert |
| 04/23/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | — | Reiterates | → Overweight | Get Alert |
| 04/08/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $6 → $6 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $3 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $3 | Reiterates | Buy → Buy | Get Alert |
| 09/07/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $3 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | → Buy | Get Alert |
| 08/01/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | — | Needham | Joseph Stringer61% | → $3 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6 | Reiterates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $6.5 → $6 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen58% | → $5 | Reiterates | → Overweight | Get Alert |
| 03/01/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | → $6.5 | Reiterates | → Buy | Get Alert |
| 01/25/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce64% | $6 → $6.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cidara Therapeutics (CDTX) stock?
The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by HC Wainwright & Co. on June 18, 2025. The analyst firm set a price target for $41.00 expecting CDTX to rise to within 12 months (a possible 92.80% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics their buy rating.
When was the last upgrade for Cidara Therapeutics (CDTX)?
The last upgrade for Cidara Therapeutics Inc happened on August 14, 2024 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Cidara Therapeutics Inc.
When was the last downgrade for Cidara Therapeutics (CDTX)?
There is no last downgrade for Cidara Therapeutics.
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on June 18, 2025 so you should expect the next rating to be made available sometime around June 18, 2026.
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a with a price target of $0.00 to $41.00. The current price Cidara Therapeutics (CDTX) is trading at is $21.27, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
